DNA SOLUTIONS

ww.dnasolutions.com

DNA Solutions have been assisting individuals around the globe with DNA Paternity & relationship analysis & were the first pioneering company offering DNA home kits to test for paternity and introduced these back in the 90’s. Many of our technical staff and management are ex-police and ex-military DNA testing forensic scientists, further enhancing the quality and range of our DNA tests. Processing occurs in our own DNA laboratory, our lab is capable of DNA ancestry testing, paternity testing, relationship tests, DNA banking and preservation, where we additionally carry out extensive research and development. We have offices and laboratories worldwide & serve thousands of individuals and organizations globally

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

DOVER TO ACQUIRE MANUFACTURER OF FLOW-MEASUREMENT DEVICES FOR BIOPHARMA AND SEMICONDUCTOR PRODUCTION APPLICATIONS

Dover | May 11, 2022

news image

Dover (NYSE: DOV) announced today that it has entered into a definitive agreement to acquire Malema Engineering Corporation ("Malema"), a designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments serving customers in the biopharmaceutical, semiconductor, and industrial sectors. Malema will become part of the PSG business unit within Dover's Pumps & Process Solutions segment. Malema's products will expand Dover'...

Read More

MARINE BIOTECHNOLOGY MARKET 2020

Publicist 360 | April 08, 2020

news image

IndustryGrowthInsights, 08-04-2020: The research report on the Marine Biotechnology Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data an...

Read More

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

news image

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More
news image

Medical

DOVER TO ACQUIRE MANUFACTURER OF FLOW-MEASUREMENT DEVICES FOR BIOPHARMA AND SEMICONDUCTOR PRODUCTION APPLICATIONS

Dover | May 11, 2022

Dover (NYSE: DOV) announced today that it has entered into a definitive agreement to acquire Malema Engineering Corporation ("Malema"), a designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments serving customers in the biopharmaceutical, semiconductor, and industrial sectors. Malema will become part of the PSG business unit within Dover's Pumps & Process Solutions segment. Malema's products will expand Dover'...

Read More
news image

MARINE BIOTECHNOLOGY MARKET 2020

Publicist 360 | April 08, 2020

IndustryGrowthInsights, 08-04-2020: The research report on the Marine Biotechnology Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data an...

Read More
news image

CYTODYN ANNOUNCES FIRST SITE IN THE SOUTHEASTERN USA TO ENROLL PATIENTS IN PHASE 2 CORONAVIRUS TRIAL

Proactive Investors | April 08, 2020

The Novant Health network cares for around 5 million patients a year at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics. CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial using leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms. Novant Health is the second trial site in the USA and the first site in th...

Read More
news image

Cell and Gene Therapy

AMYRIS PARTNERS WITH INSCRIPTA TO ENHANCE DEVELOPMENT OF SUSTAINABLE INGREDIENTS USING THE ONYX™ GENOME ENGINEERING PLATFORM

Amyris | October 06, 2021

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality. Amyris' prod...

Read More